Scynexis (SCYX) Interest & Investment Income (2013 - 2026)
Scynexis' (SCYX) quarterly Interest & Investment Income came in at $685000.0 in Q2 2026, up 34.31% on a YoY basis from $510000.0 in Q2 2025, and up 28.04% quarter-over-quarter from $535000.0 in Q1 2026.
Analysis
Scynexis (SCYX) Interest & Investment Income (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Interest & Investment Income for 14 consecutive years, with $685000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest & Investment Income rose 34.31% year-over-year to $685000.0; the trailing twelve-month figure through Jun 2026 stood at $2.1 million (down 34.11% YoY), and the FY2025 full-year result was $2.2 million, down 49.27% from the prior year.
- Interest & Investment Income climbed to $685000.0 in Q2 2026 per SCYX's latest filing, from $535000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.4 million in Q4 2023 and bottomed at $13000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $724666.7 across 5 years, with a median of $688000.0 in 2022.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income soared 17175.0% in 2022, then sank 55.49% in 2025.
- Over 5 years, Interest & Investment Income stood at $691000.0 in 2022, then surged by 97.4% to $1.4 million in 2023, then tumbled by 36.29% to $869000.0 in 2024, then plunged by 51.9% to $418000.0 in 2025, then soared by 63.88% to $685000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $685000.0, $535000.0, and $418000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 36.92 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 685,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 685,000.00 |
| Mar 31, 2026 | 535,000.00 |
| Dec 31, 2025 | 418,000.00 |
| Sep 30, 2025 | 454,000.00 |
| Jun 30, 2025 | 510,000.00 |
| Mar 31, 2025 | 776,000.00 |
| Dec 31, 2024 | 869,000.00 |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Dec 31, 2023 | 1.36 Mn |
| Sep 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | 737,000.00 |
| Mar 31, 2023 | 587,000.00 |
| Dec 31, 2022 | 691,000.00 |
| Sep 30, 2022 | 531,000.00 |
| Jun 30, 2022 | 181,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 8,000.00 |